BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, is sharing details of a new two-photon fluorescence microscopy technique to visualize minocycline skin penetration along with research that correlates the new visualization method with the company's clinical data.
In presentations at SPIE Photonics West, the company has shown how two-photon fluorescence microscopy was used to confirm data from BioPharmX's BPX-01 Phase 2a clinical trial. The trial demonstrated that the company's topical minocycline gel formulation delivered adequate minocycline to the appropriate site to target P. acnes.
Prior to initiation of clinical studies, traditional fluorescence microscopy technique and matrix-assisted laser desorption/ionization (MALDI) were used to optimize the drug delivery system and to confirm optimal treatment dose and timing of BPX-01. Traditional fluorescence microscopy was limited in sensitivity while MALDI is too costly and time-consuming for rapid optimization. The novel multi-photon imaging approach has the potential to overcome both deficiencies.
BioPharmX says BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit. The company's studies are designed to confirm whether BPX-01 can effectively treat acne with lower, and potentially safer, dosages of the antibiotic.